CDK4 and pancreatic ductal adenocarcinoma: Interestingly, recent work revealed that the combination of CDK4/6i and MEKi induces senescence in pancreatic ductal adenocarcinoma [50, 51] and suppressed tumor growth in Braf/MEK inhibitor-resistant melanoma [52].